Our Pipeline

Therapy Area	Project - Indication	Phase I	Phase II	Phase III	Filed
Reproductive Health	FE 999310 Infertility	yes
	FE 202767 Lactation		yes
	BARUSIBAN Implantation Support		yes
	REKOVELLE (recombinant human FSH) Infertility				yes
	MILPROSA Progesterone vaginal ring Luteal phase support				yes
Urology	TESTAVAN (testosterone gel) Male hypogonadism				yes
Gastroenterology	FE 203799 Indication to be determined	yes
Endocrinology
Orthopaedics	AMPLEX (B2A peptide + tricalcium phosphate ceramic granules) Foot & Ankle Fusion			yes
	PREFIX (B2A peptide + tricalcium phosphate ceramic granules) Lumbar Spine Fusion			yes
	CONDOLIASE (chrondroitin-sulfate-ABC endolyase) Radicular leg pain (e.g. sciatica) due to lumbar disc herniation			yes
Other	SELEPRESSIN Septic shock		yes

Headquarters

FERRING INTERNATIONAL CENTER S.A.
CH. DE LA VERGOGNAUSAZ 50
1162 SAINT-PREX
SWITZERLAND

TEL: +41 58 301 00 00
FAX: +41 58 301 00 10

CONTACT

global locator

This global corporate website provides general information about the global Ferring Group. For information about Ferring or its products in a specific country, please select your country in the Global Locator. FERRING, the FERRING PHARMACEUTICALS logo and other Ferring product trade names are trademarks of Ferring B.V. save where indicated otherwise.
©2016 Ferring B.V.